Skip to main content
    T

    Theriva Biologics Inc. (TOVX)

    Official site

    HEALTHCARE • BIOTECHNOLOGY • NYSE MKT

    $0.14
    -0.00 (-2.36%)

    Market Cap: $6.61M

    Last updated: Nov 17, 2026 at 11:06 AM ET

    Theriva Biologics Inc. (TOVX) Financials: Revenue, Profit and Cash Flow

    Updated Nov 12, 2026. Financial statements from company filings, amounts in US dollars.

    Theriva Biologics reported revenue of $0 for the fiscal year ended Dec 31, 2025. That year, net income was -$23.74M, operating cash flow was -$16.67M and free cash flow was -$16.70M. The quarter ended Sep 30, 2026 had revenue of $0 and net income of -$1.47M.

    Revenue and Margins

    The company reported no revenue in the fiscal year ended Dec 2025, with an operating loss of $24.05M.

    Fiscal yearRevenueGrowthGross marginOperating marginNet margin
    Dec 2025$0N/AN/AN/AN/A
    Dec 2024$0N/AN/AN/AN/A
    Dec 2023$0N/AN/AN/AN/A
    Dec 2022$0N/AN/AN/AN/A
    Dec 2021$0N/AN/AN/AN/A
    Dec 2020$0N/AN/AN/AN/A
    Dec 2019$0N/AN/AN/AN/A
    Dec 2018$0N/AN/AN/AN/A
    Dec 2017$0N/AN/AN/AN/A
    Dec 2016$0N/AN/AN/AN/A
    Annual, fiscal years ended Dec 2016 to Dec 2025

    Income Statement

    In the fiscal year ended Dec 2025, the net loss narrowed from the year before. In the quarter ended Sep 2026, the net loss narrowed from the same quarter a year earlier.

    Annual

    Line itemDec 2025Dec 2024Dec 2023Dec 2022Dec 2021Dec 2020Dec 2019Dec 2018Dec 2017Dec 2016
    Research and development$8.60M$12.03M$14.31M$11.72M$7.80M$5.13M$11.08M$11.84M$18.78M$29.11M
    Operating income-$24.05M-$26.35M-$21.43M-$21.58M-$14.27M-$10.16M-$15.66M-$17.57M-$26.25M-$39.25M
    Net income-$23.74M-$25.65M-$18.35M-$19.68M-$14.27M-$10.12M-$15.38M-$13.42M-$15.49M-$27.80M
    EBITDA-$23.92M-$26.21M-$21.29M-$21.54M-$14.19M-$9.96M-$15.42M-$13.22M-$15.27M-$27.68M
    Fiscal years ended Dec 2016 to Dec 2025

    Quarterly

    Line itemSep 2026Jun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023
    Revenue$0$0$300.00K$0$0$0$0$154.00K$0$0$0$758.00K
    Gross profit$0$0$300.00K-$27.00K$0$0$0-$27.00K$0$0$0-$39.00K
    Operating income-$1.53M-$3.29M-$2.13M-$2.06M-$4.44M-$13.13M-$4.42M-$4.58M-$7.89M-$8.49M-$5.39M-$6.21M
    Net income-$1.47M-$3.22M-$2.04M-$2.00M-$4.36M-$13.06M-$4.32M-$4.45M-$7.73M-$8.32M-$5.17M-$5.48M
    Last 12 quarters

    Balance Sheet

    As of Dec 2025, cash and equivalents exceeded total debt of $1.73M by $11.33M.

    Annual

    Line itemDec 2025Dec 2024Dec 2023Dec 2022Dec 2021Dec 2020Dec 2019Dec 2018Dec 2017Dec 2016
    Total assets$38.24M$35.35M$55.22M$71.86M$70.36M$8.41M$17.23M$30.14M$18.84M$22.50M
    Current assets$17.47M$16.28M$27.40M$45.52M$68.86M$7.93M$16.43M$29.51M$17.94M$21.57M
    Cash and equivalents$13.06M$11.61M$23.18M$41.79M$67.33M$6.23M$15.04M$28.92M$17.12M$19.05M
    Total liabilities$22.86M$16.29M$15.52M$17.30M$4.96M$3.15M$5.75M$3.69M$10.20M$20.25M
    Short-term debt$57.00K$61.00K$63.00K$3.03M$0$287.00K$249.00KN/AN/AN/A
    Long-term debt$1.67M$92.00K$162.00K$221.00K$0N/AN/AN/AN/AN/A
    Shareholder equity$15.38M$19.07M$36.96M$51.83M$65.41M-$4.77M$1.82M$17.07M-$1.50M$3.85M
    Fiscal years ended Dec 2016 to Dec 2025

    Quarterly

    Line itemSep 2026Jun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023
    Total assets$31.56M$34.86M$38.25M$38.24M$30.84M$35.83M$32.16M$35.35M$40.11M$42.39M$48.73M$55.22M
    Total liabilities$20.81M$22.67M$22.85M$22.86M$24.10M$25.21M$16.66M$16.29M$15.47M$14.74M$14.61M$15.52M
    Cash and equivalents$8.47M$11.34M$14.43M$13.06M$7.53M$12.12M$10.01M$11.61M$16.41M$16.59M$18.26M$23.18M
    Shareholder equity$10.75M$12.19M$15.40M$15.38M$6.74M$10.62M$15.50M$19.07M$24.64M$25.90M$31.39M$39.70M
    Last 12 quarters

    Cash Flow

    Operating cash flow was negative in the fiscal year ended Dec 2025.

    Annual

    Line itemDec 2025Dec 2024Dec 2023Dec 2022Dec 2021Dec 2020Dec 2019Dec 2018Dec 2017Dec 2016
    Operating cash flow-$16.67M-$16.94M-$19.00M-$19.08M-$12.89M-$12.17M-$13.87M-$17.28M-$20.20M-$27.90M
    Capital expenditures$35.00K$1.00K$202.00K$116.00K$14.00K$9.00K$0$7.00K$212.00K$569.00K
    Free cash flow-$16.70M-$16.94M-$19.20M-$19.20M-$12.90M-$12.18M-$13.87M-$17.29M-$20.42M-$28.47M
    Share repurchasesN/AN/AN/A$288.00K$0N/AN/AN/AN/AN/A
    Investing cash flow-$35.00K-$1.00K-$202.00K-$4.40M-$14.00K-$9.00K$0-$7.00K-$212.00K-$569.00K
    Financing cash flow$18.19M$5.50M$625.00K-$1.93M$74.00M$3.36M$0$29.09M$18.48M$26.71M
    Fiscal years ended Dec 2016 to Dec 2025

    Quarterly

    Line itemSep 2026Jun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023
    Operating cash flow-$2.86M-$3.08M-$2.46M-$2.88M-$4.32M-$4.71M-$4.76M-$4.69M-$3.91M-$3.45M-$4.88M-$6.54M
    Capital expenditures$5.00KN/A$0$0$19.00K$16.00K$0$0$0$1.00K$0$56.00K
    Free cash flow-$2.87MN/A-$2.46M-$2.88M-$4.34M-$4.73M-$4.76M-$4.69M-$3.91M-$3.45M-$4.88M-$6.60M
    Last 12 quarters

    Frequently Asked Questions About TOVX

    What is Theriva Biologics' annual revenue?

    Theriva Biologics reported revenue of $0 for the fiscal year ended Dec 31, 2025.

    Is Theriva Biologics profitable?

    No. Theriva Biologics reported net income of -$23.74M for the fiscal year ended Dec 31, 2025.

    How much free cash flow does TOVX generate?

    For the fiscal year ended Dec 31, 2025, operating cash flow of -$16.67M minus capital expenditures of $35.00K produced free cash flow of -$16.70M.

    How much debt does Theriva Biologics have?

    The balance sheet dated Dec 31, 2025 reported long-term debt of $1.67M, short-term debt of $57.00K and cash and equivalents of $13.06M.